Management highlighted Eisai’s neurology and oncology assets during a Scientific Day in New York, the first formal R&D briefing the Japanese pharma’s US subsidiary has held in more than 20 years operating in the country.
Eisai Inc. – the US subsidiary of Tokyo-based Eisai Co. Ltd. – showcased its neurology and oncology pipeline during a Scientific Day in New York June 29, the first formal R&D overview the company has hosted in the US since Eisai Inc. was officially established in 1995.
“Why this time?” asked Haruo Naito, CEO of the Japanese parent, opening the four-hour briefing. “We have just launched our...
Create an account to read this article
Already a subscriber?
Dawnzera joins CSL’s recently approved Andembry as new additions to the crowded hereditary angioedema prevention market. It is priced at $57k per dose, but labeling includes four- or eight-week options.
The CAR-T specialist is spending $350m to acquire the private Philadelphia-based firm, which is developing in vivo CAR-Ts using lentiviral vectors.
Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.
The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.
Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.
The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.
The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.
